Business Description
Thermo Fisher Scientific Inc
NAICS : 541380
SIC : 3826
ISIN : US8835561023
Share Class Description:
TMO: Ordinary SharesTotal Employee Number:
125,000Compare
Compare
Traded in other countries / regions
TMO.USATMO.CanadaTMOS34.Brazil0R0H.UKTN80.GermanyTMO.ArgentinaTMO.MexicoTMO.PeruTMOCL.ChileTMOF.Austria1TMO.Italy Index Membership
S&P 500Russell 1000Russell 3000MSCI World Index IPO Date
1972-06-01Description
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.1 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.81 | |||||
Debt-to-EBITDA | 3.53 | |||||
Interest Coverage | 5.78 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.79 | |||||
Beneish M-Score | -2.44 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.1 | |||||
3-Year EBITDA Growth Rate | 0.1 | |||||
3-Year EPS without NRI Growth Rate | -0.5 | |||||
3-Year FCF Growth Rate | -1.7 | |||||
3-Year Book Growth Rate | 8 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 9.63 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.07 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 83.25 | |||||
9-Day RSI | 77.47 | |||||
14-Day RSI | 74.24 | |||||
3-1 Month Momentum % | 16.48 | |||||
6-1 Month Momentum % | 2.99 | |||||
12-1 Month Momentum % | 6.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.55 | |||||
Quick Ratio | 1.18 | |||||
Cash Ratio | 0.27 | |||||
Days Inventory | 74.12 | |||||
Days Sales Outstanding | 70.99 | |||||
Days Payable | 43.47 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.29 | |||||
Dividend Payout Ratio | 0.08 | |||||
3-Year Dividend Growth Rate | 12.7 | |||||
Forward Dividend Yield % | 0.31 | |||||
5-Year Yield-on-Cost % | 0.57 | |||||
3-Year Average Share Buyback Ratio | 1.2 | |||||
Shareholder Yield % | -0.23 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 40.8 | |||||
Operating Margin % | 18.29 | |||||
Net Margin % | 15.04 | |||||
EBITDA Margin % | 26 | |||||
FCF Margin % | 15.79 | |||||
OCF Margin % | 19.45 | |||||
ROE % | 13.42 | |||||
ROA % | 6.44 | |||||
ROIC % | 8.29 | |||||
3-Year ROIIC % | -2.15 | |||||
ROC (Joel Greenblatt) % | 56.1 | |||||
ROCE % | 9.71 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 8 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 33.76 | |||||
Forward PE Ratio | 24.98 | |||||
PE Ratio without NRI | 26.33 | |||||
Shiller PE Ratio | 39.34 | |||||
Price-to-Owner-Earnings | 34.19 | |||||
PEG Ratio | 10.53 | |||||
PS Ratio | 5.1 | |||||
PB Ratio | 4.4 | |||||
Price-to-Free-Cash-Flow | 32.23 | |||||
Price-to-Operating-Cash-Flow | 26.16 | |||||
EV-to-EBIT | 29.73 | |||||
EV-to-Forward-EBIT | 30.5 | |||||
EV-to-EBITDA | 22.47 | |||||
EV-to-Forward-EBITDA | 22.49 | |||||
EV-to-Revenue | 5.84 | |||||
EV-to-Forward-Revenue | 5.54 | |||||
EV-to-FCF | 36.98 | |||||
Price-to-GF-Value | 1.05 | |||||
Price-to-Projected-FCF | 2.1 | |||||
Price-to-DCF (Earnings Based) | 1.28 | |||||
Price-to-DCF (FCF Based) | 1.73 | |||||
Price-to-Median-PS-Value | 1.06 | |||||
Earnings Yield (Greenblatt) % | 3.36 | |||||
FCF Yield % | 3.15 | |||||
Forward Rate of Return (Yacktman) % | 2.64 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:TMO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thermo Fisher Scientific Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 46,336 | ||
| EPS (TTM) ($) | 18.59 | ||
| Beta | 0.7864 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.05 | ||
| Volatility % | 26.64 | ||
| 14-Day RSI | 74.24 | ||
| 14-Day ATR ($) | 16.284388 | ||
| 20-Day SMA ($) | 586.494 | ||
| 12-1 Month Momentum % | 6.35 | ||
| 52-Week Range ($) | 435.27 - 643.99 | ||
| Shares Outstanding (Mil) | 369.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thermo Fisher Scientific Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thermo Fisher Scientific Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-01-29 08:30 | In 162 days | ||
| Fourth quarter earnings results for 2026 | 2027-01-29 | In 161 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-22 08:30 | In 63 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 62 days | ||
| USD 0.470000 Cash Dividend | 2026-09-15 | In 25 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-23 08:30 | 526.46 (+0.33%) | ||
| Second quarter earnings results for 2026 | 2026-07-23 | 526.46 (+0.33%) | ||
| USD 0.470000 Cash Dividend | 2026-06-15 | 469.34 (-1.86%) | ||
| General meeting for 2026 | 2026-05-20 13:00 | 447.81 (+1.31%) | ||
| Analyst meeting for 2026 | 2026-05-20 09:00 | 447.81 (+1.31%) |
Show
Entries
Thermo Fisher Scientific Inc Frequently Asked Questions
What is Thermo Fisher Scientific Inc(TMO)'s stock price today?
The current price of TMO is $627.55. The 52 week high of TMO is $643.99 and 52 week low is $435.27.
When is next earnings date of Thermo Fisher Scientific Inc(TMO)?
The next earnings date of Thermo Fisher Scientific Inc(TMO) is 2026-10-22 Est..
Does Thermo Fisher Scientific Inc(TMO) pay dividends? If so, how much?
The Dividend Yield %  of Thermo Fisher Scientific Inc(TMO) is 0.29% (As of Today), Highest Dividend Payout Ratio of Thermo Fisher Scientific Inc(TMO) was 0.08. The lowest was 0.04. And the median was 0.06. The  Forward Dividend Yield % of Thermo Fisher Scientific Inc(TMO) is 0.31%. For more information regarding to dividend, please check our Dividend Page.
Guru Commentaries on NYSE:TMO
Guinnessgi
Bullish
2026 Q2
2026.08 Guinness Global Innovators Commentary GBPEURUSD EN 0
Guinness Atkinson China & Hong Kong Fund
· 31 holdings
What the manager wrote
Thermo Fisher has demonstrated strong performance, with a notable increase of 14.6% in the last month. This growth reflects the company's robust fundamentals and its ability to navigate market challenges effectively. The manager highlights Thermo Fisher as a key holding, indicating confidence in its ongoing success and resilience in the healthcare sector. The positive stock selection effect from Thermo Fisher has contributed significantly to the fund's overall performance, showcasing its value as a strategic investment.
Guinnessgi
Bullish
2026 Q2
2026.08 Guinness Global Innovators Commentary GBPEURUSD EN
Guinness Atkinson China & Hong Kong Fund
· 31 holdings
What the manager wrote
Thermo Fisher has demonstrated strong performance, with a notable increase of 14.6% in the recent period. This reflects the company's robust fundamentals and its ability to navigate market challenges effectively. The manager highlights the resilience of Thermo Fisher within the healthcare sector, indicating confidence in its growth trajectory. The company is well-positioned to capitalize on ongoing trends in healthcare innovation and demand for its products and services, making it a valuable addition to the portfolio.
Press Release
Articles on Thermo Fisher Scientific Inc
EdgePoint Investment Group Inc. Trims Twist Bioscience Corp (TWST) Stake -- Shares Trade 160% Above GF Value
6 hours ago
EdgePoint Investment Group Inc. Adds to RB Global Inc (RBA) Stake -- Shares Look 18% Undervalued on GF Value
6 hours ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers